Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with CL Leukaemia and Heart Failure

Trial Identifier: D8223C00016
Sponsor: AstraZeneca
Collaborator:
Fortrea Inc.
CALYX Inc.
eResearch Technology Inc.
CISCRP Inc.
Start Date: February 2025
Primary Completion Date: August 2030
Study Completion Date: August 2030
Condition: Congestive Heart Failure

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CZ Brno, CZ, 625 00
CZ Hradec Králové, CZ, 500 05
CZ Praha 10, CZ, 10034
ES Barcelona, ES, 08003
ES Madrid, ES, 28040
ES Sevilla, ES, 41009
GB Bournemouth, GB, BH7 7DW
GB Oxford, GB, OX3 7LE
GB Plymouth, GB, PL6 8DH
GB Romford, GB, RM7 0AG
GB Stockton, GB, TS19 8PE
GB Sutton Coldfield, GB, B74 3UP
IT Cagliari, IT, 09121
IT Firenze, IT, 50134
IT Milan, IT, 20132
IT Milano, IT, 20122
IT PAVIA, IT, 27100
IT PERUGIA, IT, 06156
PL Krakow, PL, 30-727
PL Poznan, PL, 60-693
US, NC Charlotte, NC, US, 28204
US, OH Columbus, OH, US, 43210
US, PA Philadelphia, PA, US, 19104